Of note, all NSCLC cell lines tested harbor KRAS mutations, and two of three cell lines (NCI‐H460, and A549) have concurrent KRAS and LKB1 mutations [28, 35, 36, 37, 38]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.